# Progress Note 06 — Focused Visit (Care-plan review)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Thomas Jefferson (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-EN005-SYN
- Date: 2026-08-13
- Fictional facility: St. Posthumous Health Center
- Fictional author: Nathaniel Beaumont-Ruiz, MD
- Calendar frame: modern shifted

- Visit type: Focused Visit (Care-plan review)

## Chief complaint

Three-month review of migraine prevention. **S**

## History of present illness

Mr. Jefferson returns twelve weeks after starting propranolol and eight weeks after raising it to 120 mg. His diary shows 3 migraine days in the past four weeks and one in the four weeks before that, with no attack lasting more than a day; each was treated with sumatriptan and naproxen, and he was pain-free within two hours in two of the three. Acute medicine was used on 3 days. He has had no tiredness, dizziness or wheeze, and his fingers are cold only on cool mornings. His mood is good. He saw the hand therapist five weeks ago, wears a wrist splint for long writing and now writes for about two hours with breaks. His HIV, hepatitis C and hepatitis B tests from the preventive visit were nonreactive and his FIT was negative, and he was told by phone. **S**

| Element | Detail |
|---|---|
| Migraine days | 3 in the past four weeks, from 13 before prevention |
| Acute medicine | 3 days; pain-free at two hours in 2 of 3 attacks |
| Propranolol | 120 mg each evening for eight weeks; cold fingers on cool mornings |
| Disability | MIDAS 13 (grade III), from 39; HIT-6 54, from 66 |
| Mood | PHQ-9 3; GAD-7 4 |
| Screening results | HIV, hepatitis C and hepatitis B nonreactive; FIT negative |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Constitutional | Negative | Energy good |
| Respiratory | Negative | No wheeze or breathlessness |
| Neurological | Positive | Three short migraine attacks in four weeks; no new features |
| Musculoskeletal | Positive | Right wrist stiff after long writing, better with the splint |
| Psychiatric | Negative | Mood good; PHQ-9 3 |

5 systems reviewed. **S**

## Current medications

- Naproxen 500 mg oral tablet, one tablet with food at the start of a headache, may repeat once after 12 hours; no more than two days a week **S**
- Metoclopramide 10 mg oral tablet, one tablet with the naproxen when a headache brings nausea; no more than two days a week **S**
- Sumatriptan 100 mg oral tablet, one tablet with naproxen early in a migraine attack, may repeat once after 2 hours; no more than two tablets a day and no more than nine days a month **S**
- Propranolol extended-release 120 mg oral capsule, one capsule each evening, for migraine prevention **S**

## Allergies

- No known allergy **S**

## Objective

BP 112/72 mmHg; pulse 58 bpm; respirations 14/min; temperature 36.6 °C; oxygen saturation 98% on room air; weight 76.6 kg; BMI 21.4 kg/m². All vital signs are synthetic.

MIDAS 1, work days missed: 3 d; MIDAS 2, work days at half productivity or less: 5 d; MIDAS 3, household work days missed: 1 d; MIDAS 4, household days at half productivity or less: 2 d; MIDAS 5, family, social or leisure days missed: 2 d; PHQ-9: 3; GAD-7: 4. All results are synthetic.

## Change since baseline

- MIDAS 1, work days missed: 8 d at baseline, 3 d at this visit **S**
- MIDAS 2, work days at half productivity or less: 14 d at baseline, 5 d at this visit **S**
- MIDAS 3, household work days missed: 4 d at baseline, 1 d at this visit **S**
- MIDAS 4, household days at half productivity or less: 6 d at baseline, 2 d at this visit **S**
- MIDAS 5, family, social or leisure days missed: 7 d at baseline, 2 d at this visit **S**
- PHQ-9: 6 at baseline, 3 at this visit **S**
- GAD-7: 7 at baseline, 4 at this visit **S**

## Immunizations given today

- Hepatitis B vaccine (HepB-CpG), second of two doses **S**

## Physical examination

| System | Finding |
|---|---|
| General | Well; blood pressure 112/72, pulse 58 |
| Neurological | Normal |
| Musculoskeletal | Right wrist range of motion unchanged; grip slightly stronger |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Migraine without aura on propranolol** (G43.009). A good response: monthly migraine days down from 13 to 3, more than the 50% reduction sought, with MIDAS 39 to 13 and HIT-6 66 to 54. The MIDAS still counts the end of the spring bout in its three-month recall. Propranolol 120 mg is well tolerated. Acute medicine on 3 days a month, far within the overuse limits. PHQ-9 3 on propranolol. **S**
   - Continue propranolol 120 mg each evening for six to twelve months, then discuss a slow taper if he stays well.
   - If a bout breaks through, a CGRP monoclonal antibody is the next option.
   - Continue sumatriptan with naproxen as needed and the diary.
2. **Stiff right wrist after an old dislocation** (M25.631). Hand therapy, a splint and dictation have lengthened his writing time to about two hours. **S**
   - Continue the home exercises and the splint for long writing.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Examination | Red-flag screen (SNNOOP10): systemic signs, neurological signs, sudden or new pattern, onset after 50, positional or Valsalva features, papilledema, progressive course | Every visit | Completed today | No red flags |
| Survey | Headache diary: headache and migraine days, attack features, triggers | Every visit | Completed today | 3 migraine days in the past four weeks; 1 in the four weeks before |
| Medication safety | Acute-medicine days (medication overuse headache limits: triptan fewer than 10, NSAID fewer than 15 days a month) | Every visit | Completed today | Acute medicine on 3 days in four weeks |
| Medication safety | Acute treatment response (pain-free at two hours, return to work) | Every visit | Completed today | Pain-free at two hours in 2 of 3 attacks |
| Medication safety | Propranolol tolerability: pulse, blood pressure, tiredness, exercise tolerance, wheeze, cold hands, sleep | Four weeks after starting or changing the dose, then each visit | Completed today | Pulse 58, blood pressure 112/72; cold fingers on cool mornings only; no wheeze or tiredness |
| Examination | Preventive efficacy (at least 50% fewer migraine days) | At two to three months on an adequate dose | Completed today | Migraine days 13 to 3 in four weeks (77% fewer) after twelve weeks, eight of them on 120 mg |
| Survey | Disability (MIDAS, recorded as its five items, and HIT-6) | At baseline and after about three months of prevention | Completed today | MIDAS items 3, 5, 1, 2 and 2 days, total 13 (grade III), from 39; HIT-6 54, from 66 |
| Survey | Mood (PHQ-9) and anxiety (GAD-7), including on a beta-blocker | At baseline, four to six weeks after starting a preventive that can affect mood, then at each review | Completed today | PHQ-9 3, item 9 scored 0; GAD-7 4 |
| Imaging | Neuroimaging | Only for red flags or a change in pattern | Not indicated | No red flags or change in pattern |
| Self-management | Sleep, meals, caffeine and work-stress plan | Every visit | Completed today | Sleep, meals and caffeine steady; breaks from reading every hour |
| Referral | Occupational therapy visit for the right wrist and writing | Within four weeks of intake | Completed today | Seen by the hand therapist five weeks ago; splint and home exercises |

## Goal progress

- A two-week headache diary that allows a firm diagnosis. Outcome by 2026-05-21: Diary of 14 days kept; ICHD-3 criteria for migraine without aura met; no red flags. **S**
- Monthly migraine days reduced by at least half within three months of starting prevention. Outcome by 2026-08-13: From 13 migraine days in the four weeks before prevention to 3 in the last four weeks. **S**
- Acute medicine on no more than two days a week, so that medication overuse headache does not develop. Outcome by 2026-08-13: Acute medicine on 3 days in the last four weeks; no combination analgesic or caffeine pill since intake. **S**
- Pain-free within two hours of acute treatment in most attacks. Outcome by 2026-08-13: Pain-free at two hours in 6 of 8 attacks treated with sumatriptan and naproxen since the consultation. **S**
- Lower headache-related disability. Outcome by 2026-08-13: MIDAS 39 (grade IV) to 13 (grade III); the three-month recall still includes the end of the May bout. **S**
- Write for longer without wrist pain. Outcome by 2026-08-13: Dictation and a wrist splint for long writing; about two hours with breaks. **S**

## Guideline basis

- Headache Classification Committee of the International Headache Society (IHS). The International Classification of Headache Disorders, 3rd edition (2018), International Headache Society (Cephalalgia 2018;38(1):1-211)
- The American Headache Society Consensus Statement: Update on integrating new migraine treatments into clinical practice (2021), American Headache Society (Headache 2021;61(7):1021-1039)
- Calcitonin gene-related peptide-targeting therapies are a first-line option for the prevention of migraine: An American Headache Society position statement update (2024), American Headache Society (Headache 2024;64(4):333-341)
- The American Headache Society Position Statement On Integrating New Migraine Treatments Into Clinical Practice (2019), American Headache Society (Headache 2019;59(1):1-18)
- Prevention of Episodic Migraine Headache Using Pharmacologic Treatments in Outpatient Settings: A Clinical Guideline From the American College of Physicians (2025), American College of Physicians (Annals of Internal Medicine 2025;178(3):426-433)
- Choosing wisely in headache medicine: the American Headache Society's list of five things physicians and patients should question (2013), American Headache Society (Headache 2013;53(10):1651-1659)
- CMID: Clinical Monitoring Intelligence Database, depression, bipolar, and mood disorders monograph (2026), Aether Forge

## Follow-up

- Second hepatitis B vaccine dose given today. Review in three months, or sooner if a bout breaks through. Influenza and COVID-19 vaccines in the autumn. **S**

